LeMaitre Vascular (NASDAQ:LMAT) Upgraded to “Hold” at Freedom Capital

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by equities researchers at Freedom Capital to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on LMAT. Barrington Research raised their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Roth Mkm reiterated a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Finally, Wells Fargo & Company increased their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.80.

LeMaitre Vascular Trading Down 0.4%

NASDAQ LMAT opened at $108.75 on Tuesday. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $115.33. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $98.21 and a 200-day moving average of $90.43. The company has a market cap of $2.48 billion, a PE ratio of 43.33, a PEG ratio of 3.14 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Insider Activity

In other news, CEO George W. Lemaitre sold 150,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. This trade represents a 8.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider directly owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the business. Cornerstone Planning Group LLC increased its position in LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the period. MAI Capital Management acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $38,000. First Horizon Corp acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $39,000. Geneos Wealth Management Inc. increased its holdings in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at approximately $47,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.